600666.SH
奥瑞德
SSE · Healthcare · Drug Manufacturers - General · CN
CNY 3.38
−2.87%Year over year
Reported trailing growth
- Revenue
- +29.3%
- EBITDA
- —
- EBIT
- +233.3%
- EPS
- +186.1%
- Free cash flow
- +22.0%
- Operating cash flow
- +70.2%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -4.3%
- EBITDA
- -26.3%
- EBIT
- -34.9%
- Net income
- +32.7%
- EPS
- +33.3%
- Free cash flow
- +92.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026